Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the ...

The warning—which sent Dexcom’s stock down about 7% in aftermarket trading over the ... first European manufacturing site, bringing 1,000-plus jobs to Ireland Dexcom said it has “already ...

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

U.S. equities jumped at midday on signs the tariffs planned for April 2 by President Donald Trump won't affect as many ...

The company expects to launch Omnipod 5 in Belgium and Switzerland with Abbott’s FreeStyle Libre 2 Plus, and Dexcom G6 and G7 sensor ... a compound annual rate of 7.92% between 2024 and 2034.

Individuals transitioning from multiple daily injections to the Omnipod 5 system experienced an average HbA1c reduction of ...

Technosphere insulin, a rapid-acting human insulin administrated through an inhaler, was associated with reductions in HbA1c ...

Over 13 weeks, drops in HbA1c averaged 0.9 percentage points (from 8.2% at baseline to 7.3%) in people assigned ... used in conjunction with a Dexcom G6 CGM sensor that can be used with NovoLog ...

Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous glucose ...

Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today announced publication by The New England Journal of Medicine (NEJM) of positive results from the ...